6533b86ffe1ef96bd12cdf20

RESEARCH PRODUCT

Metalloproteinases and Tissue Inhibitors in Generalized Myasthenia Gravis. A Preliminary Study

Vincenzo Di StefanoChiara TubioloAndrea GagliardoRosalia Lo PrestiMaria MontanaMassimiliano TodiscoAntonino LupicaGregorio CaimiCristina TassorelliBrigida FierroFilippo BrighinaGiuseppe Cosentino

subject

neuromuscular junction.matrix metalloproteinases; anti-AChR antibodies; myasthenia gravis; neuromuscular junctionmatrix metalloproteinaseGeneral Neuroscienceanti-AChR antibodiemyasthenia gravi

description

Introduction: Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) have recently been proposed as promising biomarkers in different immune-mediated disorders. We evaluated the plasma levels of MMP-9 and MMP-2 and their tissue inhibitors TIMP-1 and TIMP-2 in a patients’ cohort with generalized myasthenia gravis (MG). Methods: Plasma concentrations of MMP-9, MMP-2, TIMP-1 and TIMP-2 were evaluated in 14 patients with generalized MG and 13 age- and sex-matched healthy controls. The severity of disease was assessed by the modified Osserman classification. Results: Compared to the healthy subjects, MG patients had increased plasma concentrations of MMP-9, but reduced plasma levels of MMP-2 and TIMP-1. MG patients also showed a positive correlation between MMP-2 concentrations and disease severity. An increase in MMP-9 levels and MMP-9/TIMP-1 ratio and a decrease in MMP-2 levels and MMP-2/TIMP-2 ratio were detected in patients with generalized MG. Higher levels of MMP-2 correlated with greater disease severity. Discussion: Our preliminary findings suggest that MMPs and TIMPs could play a role in the pathogenesis of MG and might be associated with the risk of clinical deterioration.

yearjournalcountryeditionlanguage
2022-10-26
10.3390/brainsci12111439https://hdl.handle.net/10447/585255